CPNE3, a member of a Ca 2+ -dependent phospholipid-binding protein family, was identified as a ligand of ERBB2 and has a more general role in carcinogenesis.
CPNE3, a member of a Ca 2+ -dependent phospholipid-binding protein family, was identified as a ligand of ERBB2 and has a more general role in carcinogenesis.
Here, we identified the prognostic significance of CPNE3 expression in acute myeloid leukemia (AML) patients based on two datasets. In the first microarray dataset (n = 272), compared to low CPNE3 expression (CPNE3 low ), high CPNE3 expression (CPNE3 high ) was associated with adverse overall survival (OS, P < 0.001) and event-free survival (EFS, P < 0.001). In the second independent group of AML patients (TCGA dataset, n = 179), CPNE3
high was also associated with adverse OS and EFS (OS, P = 0.01; EFS, P = 0.036). Notably, among CPNE3 high patients, those received allogenic hematopoietic cell transplantation (HCT) had longer OS and EFS than those with chemotherapy alone (allogeneic HCT, n = 40 vs chemotherapy, n = 46), but treatment modules played an insignificant role in the survival of CPNE3 low patients (allogeneic HCT, n = 32 vs chemotherapy, n = 54). These results indicated that CPNE3 high is an independent, adverse prognostic factor in AML and might guide treatment decisions towards allogeneic HCT. To understand its inherent mechanisms, we investigated genome-wide gene/microRNA expression signatures and cell signaling pathways associated with CPNE3 expression. In conclusion, CPNE3 high is an adverse prognostic biomarker for AML. Its effect may be attributed to the distinctive genome-wide gene/ microRNA expression and related cell signaling pathways.
A cute myeloid leukemias (AML), which harbor mutations and aberrantly expressed genes, (1) microRNA, (2) lncRNA (3) and changes in DNA methylation that are potential prognostic markers, (4) are a group of myeloid malignancies with remarkably heterogeneous outcomes. (5) The need to find effective prognostic biomarkers is pressing and has become a research hotspot.
ERBB signaling pathway, a paradigm for oncogene addiction, (6) promotes AML growth. (7) ERBB2, which can promote breast cancer growth, metastasis and drug-resistance, is an important factor of ERBB signaling pathway. (8) CPNE3, as a phosphoprotein with associated kinase activity (9) and a novel metastasis-promoting gene in non-small-cell lung cancer, (10) has been identified as a ligand of ERBB2 and has a more general role in carcinogenesis. (11) Jun activation domain-binding protein 1 (Jab1) can enhance the ERBB2-binding ability of CPNE3, further activating the ERBB signaling pathways involved in breast cancer cell pathogenesis. (12) According to the role of ERBB2 in the pathogenesis of carcinogenesis, it was speculated that the expression of CPNE3 might be related to prognosis in patients with AML. Here, we demonstrate CPNE3 high as an adverse prognostic biomarker for AML based on analysis of two separate datasets. We also explore the distinctive gene/microRNA patterns and cell signaling pathways associated with CPNE3 expression in AML patients. Original Article www.wileyonlinelibrary.com/journal/cas Fu et al.
Methods
Patients. The first cohort was derived from a whole AML cohort (n = 272, aged <60 years) diagnosed and collected at Erasmus University Medical Center (Rotterdam) between 1990 and 2008, approved by the institutional review boards at Weill Cornell Medical College and Erasmus University Center, and all subjects provided written informed consent in accordance with the Declaration of Helsinki. All patients were uniformly treated under the study protocols of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON; details of the therapeutic protocol are available from http:// www.hovon.nl). All samples were collected at diagnosis containing 80%-100% blast cells after thawing. Total RNA from mononuclear cells was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification. CPNE3 expression values were measured by Affymetrix HGU133 plus 2.0 arrays. All clinical, cytogenetic and molecular information as well as microarray data of these patients were publicly accessible at the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo, GSE6891). (13) The second cohort was derived from The Cancer Genome Atlas (TCGA) dataset, including 200 clinically annotated adult de novo AML samples. In this cohort, RNA sequencing for 179 samples and microRNA sequencing for 194 samples has been reported previously. (14) These sequencing data provided exact measures for expression levels. Detailed descriptions of clinical and molecular characteristics were also provided. All these data were publicly accessible from the TCGA website. Written informed consent was obtained from all patients, and was approved by the human studies committee at Washington University.
Statistical analyses. Overall survival (OS) was defined as the time from the date of diagnosis to death due to any cause.
Event-free survival (EFS) was defined as the time from the date of diagnosis to removal from the study due to the absence of complete remission, relapse or death from any cause. Statistical distribution and quartiles of CPNE3 expressions were used to define the optimal cut-off. First, CPNE3 expression was found to be normally distributed in AML patients (Fig. S1a) . Second, all the AML patients were divided into four subgroups (Q1: <25%, Q2: 25%-50%, Q3: 50%-75%, Q4: >75%) based on the quartile of CPNE3 expression value; however, no significant difference was observed between Q1 and Q2 (OS: Q12, P = 0.169), just as for the result for Q23 and Q34 (OS: Q23, P = 0.132, Q34, P = 0.128, respectively). (Fig. S1b) . Thus, we chose median value of CPNE3 expression as the cut-off, and defined the highest 50% CPNE3 expressers and the lowest 50% CPNE3 expressers as CPNE3 high and CPNE3 low , respectively. In the first cohort, microarray expression profiles were obtained by Affymetrix Human Genome 133 plus 2.0 and U133A Gene Chips from GSE6891 data. All experiments' design, quality control and data normalization were in line with the standard Affymetrix protocols. To investigate the associations between CPNE3 expression levels and clinical, molecular characteristics, the Fisher exact and Wilcoxon rank-sum tests were used for hypothesis testing with categorical and continuous variables, respectively. Multivariate Cox proportional hazard models were employed to study the associations between CPNE3 expression levels and OS and EFS in the presence of other known risk factors. The KaplanMeier method and the log-rank test were utilized to estimate the association between OS, EFS and CPNE3 expression. Student's t-test and multiple hypothesis correction (false discovery rate, FDR) were used to identify differences in gene/microRNA expression in CPNE3 high and CPNE3 low groups. The statistical cutoff values were an absolute fold-change (FC) ≥1.5 and an adjusted P-value ≤0.05. In the second cohort, expression data was obtained with whole-genome highthroughput sequencing. The associations between CPNE3 expression and the OS, EFS and RFS were analyzed using the Kaplan-Meier method and the log-rank test. All analyses were performed using the R 3.1.1 software packages.
Results
Differences in clinical and molecular characteristics between CPNE3 high and CPNE3 low groups. We analyzed the impact of CPNE3 mRNA expression on clinical and molecular characteristics and clinical outcome in AML patients (Table 1) 
high have a significantly shorter survival time in the entire AML (AML: OS, P < 0.001; EFS, P < 0.001, n = 272), National Comprehensive Cancer Network (NCCN) criteria of intermediate risk AML (IR-AML) (IR-AML: OS, P = 0.015; EFS, P = 0.021, n = 135) and cytogenetically normal AML (CN-AML) (CN-AML: OS, P = 0.003; EFS, P = 0.015, n = 129). CPNE3 expression showed significant associations with FAB classifications of AML. More patients with AML-M4 fell into the CPNE3 high group (P < 0.001), while more patients with AML-M1 and AML-M2 fell into the CPNE3 low group (P = 0.001 and P < 0.001, respectively). In the whole cohort of AML and CN-AML, more patients with AML-M5 fell into CPNE3 high groups (P = 0.006, P = 0.02). The fact that M4 and M5 subtypes would readily develop chemotherapy resistance, suggests that CPNE3 high might be an adverse prognostic factor of AML. Compared with CPNE3 low in the entire AML cohort, CPNE3
high carried more wild-type CEBPA (P < 0.001) and fewer double CEBPA mutations (P < 0.001), which were also shown after risk stratification by IR-AML and CN-AML. In addition, we found that CPNE3
high was associated with FLT3-ITD/NPM1
WT in CN-AML (P = 0.02). Both wild type of CEBPA and FLT3-ITD/NPM1
WT represented poor molecular characteristics in AML patients. (15, 16) These results indicated that CPNE3
high might be a useful prognosticator and a substitute for other molecular prognosticators.
CPNE3
high was associated with adverse outcomes. We also analyzed the impact of CPNE3 mRNA expression on clinical outcome in AML patients (Fig. 1) . CPNE3 high was confirmed as an adverse prognosticator not only for the entire AML (AML: OS, P < 0.001; EFS, P < 0.001) and IR-AML (IR-AML: OS, P = 0.001; EFS, P = 0.005), but also for CN-AML (CN-AML: OS, P = 0.001; EFS, P = 0.007) and the European LeukemiaNet (ELN) Intermediate-I category (ELN Intermediate-I: OS, P < 0.001; EFS, P = 0.0027, n = 99).
CPNE3 expression was associated with shorter overall survival and event-free survival in multivariate analyses. To further assess the prognostic significance of CPNE3 expression, multivariable OS/EFS models were constructed after adjusting for established prognostic factors (Table 2 ). For OS, CPNE3 high was proved to be a high-risk factor not only in the entire cohort of AML (HR = 1.71, P = 0.001), but also in the refined risk classifications, IR-AML (HR = 1.71, P = 0.03) and CN-AML (HR=2.06, P = 0.004) sub-categories. Other factors associated with worse OS in the entire cohort of AML were: negative CBF (AML1-ETO and CBFΒ-MYH11, P = 0.017), negative double CEBPA mutations (P = 0.025) and negative NPM1
Mut /FLT3 WT (P = 0.0017). Other factors associated with worse OS in IR-AML were: negative double CEBPA mutations and negative NPM1
Mut /FLT3 WT (P = 0.05 and P = 0.04, respectively). In the multivariable model for EFS, CPNE3
high was also proved as a high-risk factor in the cohorts of entire AML, IR-AML and CN-AML (P = 0.0007, P = 0.049 and P = 0.02, respectively). Other factors associated with poorer EFS in the cohort of AML were negative CBF and negative NPM1
Mut /FLT3 WT (P = 0.02 and P = 0.028, respectively).
Associations between genome-wide gene-expression profiles and CPNE3 expression. First, to further explore the role of CPNE3 in leukemogenesis, we derived CPNE3-associated gene-expression profiles in the cohort CN-AML patients who had relatively uniform cytogenetical backgrounds. A total of 388 upregulated and 99 downregulated genes that were significantly associated with CPNE3 expression (P < 0.05, fold change = 1.5) were identified (Fig. 2a) . These genes are presented in the aberrant expression heat map (Fig. 2b) .
Associations between genome-wide microRNA profiles and CPNE3 expression. Second, we analyzed TCGA-derived micro-RNA genome-wide profiles obtained by whole-genome high- throughput sequencing. A total of 145 microRNA were strongly in association with CPNE3 expression (P < 0.05) (Fig. 2c) , including the downregulation of miR-181 family (miR-181a, P = 0.001; miR-181b, P = 0.003; miR-181c, P < 0.001; miR-181d, P < 0.001) (Fig. 2d) .
CPNE3-associated cell signaling pathways. Third, dysregulation of cell signaling pathways in the Molecular Signatures Database (MSigDB) (17) were used to assess the leukemogenic processes associated with CPNE3 expression. Using mean expression of all genes in a pathway to quantify its expression level, 14 downregulated and 38 upregulated pathways were found to be significantly associated with CPNE3 high (P < 0.05) (Fig. 2e) . Of note, several important tumorigenic pathways were significantly upregulated, including "ERBB signaling pathway," "JAK/STAT signaling pathway," (18) "glycolysis/gluconeogenesis," (19) "VEGF signaling pathway" (20) and "Notch signaling pathway" (Fig. 2f) . (21) Association between CPNE3 high and adverse outcomes was confirmed by TCGA dataset. The prognostic value of CPNE3 high in AML was also found in another independent cohort obtained from The Cancer Genome Atlas (TCGA) database (n = 179, RNA-Seq data obtained through high throughput sequencing). Among the AML and CN-AML patients, CPNE3 high patients had significantly adverse OS and EFS compared to CPNE3 low patients (AML: OS, P = 0.01; EFS, P = 0.036), (CN-AML: OS, P = 0.018; EFS, P = 0.063) (Fig. 3a,b) . In the allogeneic HCT group, there were no significant differences in OS and EFS between CPNE3 high and CPNE3 low groups (OS, P = 0.261; EFS, P = 0.949) (Fig. 3c,  d ). However, in the chemotherapy group, CPNE3 high had significantly worse OS and EFS than CPNE3 low patients (OS, P = 0.004; EFS, P = 0.011) (Fig. 3c,d ). Moreover, CPNE3 high patients had longer OS and EFS after allogeneic HCT than those receiving only chemotherapy (OS, P < 0.001; EFS, P = 0.006, respectively), but treatment modules play an insignificant role in the survival of CPNE3 low patients (allogeneic HCT versus chemotherapy-only; OS, P = 0.392; EFS, P = 0.567) (Fig. 3c,d ).
Discussion
The identification of prognostic factors in AML is important for the development of new targeted therapies and riskstratified treatment strategies for AML patients. CPNE3 was identified as a ligand of ERBB2, which is an important factor of ERBB signaling pathway that promotes AML growth. We found that CPNE3 showed higher expression in myelocyte, metamyelocytes and monocytes, while lower expression in early promyelocyte (Fig. S2 ) using publicly available expression data (http://servers.binf.ku.dk/bloodspot/), which may explain why more patients with AML-M4 and AML-M5 fell into the CPNE3 high group, while more patients with AML-M1 and AML-M2 fell into the CPNE3 low group in the first cohort of AML patients. In the first cohort of AML patients, CPNE3
high also acted as an independent adverse prognostic factor in the entire cohort, the NCCN intermediate risk subgroup, the CN-AML subgroup, as well as the ELN Intermediate-I subgroup. Those results indicated that CPNE3
high is an adverse prognostic biomarker for AML and could be used to refine the risk stratification for NCCN IR-AML and ELN Intermediate-I AML sub-groups. To further confirm the prognostic significance of CPNE3, we have demonstrated that CPNE3 high was associated with shorter OS and EFS in the second cohort of AML patients (TCGA database). Notably, CPNE3
high patients had longer OS and EFS after receiving allogeneic HCT than chemotherapyonly patients, but similar differences between treatment modules were not observed in CPNE3 low patients. These results confirmed that CPNE3 high is an independent, adverse prognostic factor in AML and indicated that the expression of CPNE3 may guide treatment decisions towards allogeneic HCT.
The mechanisms underlying the association between CPNE3 high and adverse treatment outcomes are unclear. In the present study, we analyzed gene and microRNA expression, and cell signaling pathways to identify biological pathways that are associated with CPNE3 expression in AML. First, it was determined that the distinctive genome-wide gene expression patterns are significantly associated with CPNE3 expression. Second, the CPNE3-associated microRNA profile was found to be associated with CPNE3 expression, as it included miR-181 family, which were proposed as tumor suppressors; in addition, their downregulation predicts adverse prognosis in AML. (22) (23) (24) (25) HOXA9, as well as PBX3 downstream of HOXA9, could block apoptosis and promote cell growth of AML cells. (26) HOXA9 and PBX3 are direct targets of miR-181. (24) Accumulating evidence indicates that miR-181 family acts as a diagnostic marker and a potential therapeutic target for AML. (27) MiR-181a/b-enhanced drug sensitivity in chronic lymphocytic leukemia cells (28) and miR-181a could also enhance the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib. (29) Third, the distinctive cell signaling pathways were found to be associated with CPNE3 expression. These three major findings supported that CPNE3 was possibly involved in the leukemogenesis of AML and might contribute to an adverse outcome.
In summary, CPNE3 high is an independent prognostic factor for adverse prognosis in AML patients and its presence should favor allogeneic HCT in AML. Our results also indicate that CPNE3 expression can be used to refine the risk stratification for IR-AML and ELN intermediate-I AML sub-groups. Considering the high accuracy of high-throughput sequencing just as for real-time quantitative PCR (qPCR), (30) AML patients from the TCGA database further confirmed our results regarding the prognosis of CPNE3. In CN-AML patients, distinctive gene/microRNA expression profiles and cell signaling pathways associated with CPNE3 expression provide further insights into CPNE3-related leukemogenic processes.
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